Recurrent Nasopharyngeal Carcinoma Clinical Trial
Official title:
Neoadjuvant-Adjuvant Versus Adjuvant-Only Therapy Combined With Endoscopic Surgery in Advanced Recurrent Nasopharyngeal Carcinoma:A Multicenter Randomized Controlled Trial
A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy
Eligible patients are randomized into the control group and the experimental group. Patients in the experimental group would be administrated 2 courses of neoadjuvant therapy before surgery.After endoscopic surgery, patients would continue to receive 2-4 courses of chemotherapy and 8 courses of immunotherapy. Patients in the control group would firstly receive endoscopic surgery, followed by chemotherapy and immunotherapy. In total, 4 to 6 courses of chemotherapy and 10 courses of immunotherapy would be administrated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06010095 -
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03639467 -
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06029270 -
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Recruiting |
NCT03666221 -
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05350891 -
Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC
|
Phase 2 | |
| Active, not recruiting |
NCT04586088 -
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
|
Phase 2 | |
| Active, not recruiting |
NCT04405622 -
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
|
Phase 2 | |
| Not yet recruiting |
NCT04215510 -
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
|
Phase 3 | |
| Recruiting |
NCT03930498 -
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03907826 -
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
|
Phase 3 | |
| Recruiting |
NCT04376866 -
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
|
Phase 3 | |
| Not yet recruiting |
NCT05432219 -
A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Recruiting |
NCT04425265 -
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
|
N/A | |
| Not yet recruiting |
NCT03689556 -
Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy
|
||
| Not yet recruiting |
NCT03210389 -
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
|
Phase 2 | |
| Completed |
NCT01392235 -
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
| Completed |
NCT01370070 -
MK-2206 in Recurrent Nasopharyngeal Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT06228079 -
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
|
Phase 3 | |
| Terminated |
NCT04458909 -
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
|
Phase 3 | |
| Withdrawn |
NCT04231864 -
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
|
Phase 2 |